MedTrace Logo

Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee

NCT02139319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-08-25

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of the drug product at each dose level.

Conditions

Interventions

DRUG

Botulinum toxin

DRUG

Placebo

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Q-Med AB · Galderma R&D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139319 on ClinicalTrials.gov